Enteris BioPharma, Inc. is a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) offering total integrated CMC and CDMO service support including pre-formulation, proprietary and non-proprietary formulation development, analytical research and development, quality assurance, and cGMP clinical and commercial manufacturing of pharmaceutical dosage forms.
Enteris BioPharma’s proprietary drug delivery technologies include Peptelligence® and ProPerma™ which are the subject of numerous feasibility studies and active development programs, several of which are in late-stage clinical development. Enteris BioPharma’s new purpose-built, state-of-the-art facility equipped to handle myriad active pharmaceutical ingredients (APIs), including dedicated processing and containment areas for high potency active pharmaceutical ingredients (HPAPIs).
Additionally, Enteris BioPharma is advancing an innovative internal product pipeline of oral tablet reformulations of drug products that address significant treatment opportunities for which there is no oral delivery option. Enteris BioPharma’s most advanced internal product candidate, Ovarest® (oral leuprolide tablet), is an oral peptide being developed for the treatment endocrine disorders. Tobrate™ (oral tobramycin tablet) is also being developed by Enteris BioPharma for the treatment of uncomplicated urinary tract infection (uUTI).
Enteris BioPharma is an independent, wholly-owned subsidiary of SWK Holdings Corporation, a publically traded company (Nasdaq: SWKH) and offers innovative formulation solutions and manufacturing services. Enteris has access to capital and resources that it can direct towards expansion and growth opportunities.